List of Lorbrena drug patents

Lorbrena is owned by Pfizer.

Lorbrena contains Lorlatinib.

Lorbrena has a total of 4 drug patents out of which 0 drug patents have expired.

Lorbrena was authorised for market use on 02 November, 2018.

Lorbrena is available in tablet;oral dosage forms.

Lorbrena can be used as treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer, progressed on: crizotinib + at least 1 other alk inhibitor for metastatic disease; or alectinib, or ceritinib as first alk inhibitor for metastatic disease.; treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk)-positive as detected by an fda-approved test.

Drug patent challenges can be filed against Lorbrena from November, 2022.

The generics of Lorbrena are possible to be released after 04 October, 2038.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8680111 PFIZER Macrocyclic derivatives for the treatment of diseases
Mar, 2033

(10 years from now)

US10420749 PFIZER Crystalline form of lorlatinib free base
Jul, 2036

(13 years from now)

US11299500 PFIZER Crystalline form of lorlatinib free base hydrate
Oct, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020376 PFIZER Crystalline form of lorlatinib free base
Jul, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 2, 2023
Orphan Drug Exclusivity (ODE) Mar 3, 2028
New Indication (I) Mar 3, 2024

Drugs and Companies using LORLATINIB ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 02 November, 2018

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer, progressed on: crizotinib + at least 1 other alk inhibitor for metastatic disease; Or alectinib, or ceritinib as first alk inhibitor for metastatic disease.; Treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk)-positive as detected by an fda-approved test

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in